Knowledge of the detailed mechanism by which proteins such as human αB- crystallin and human lysozyme inhibit amyloid beta (Aβ) peptide aggregation is crucial for designing treatment for Alzheimer's disease. This evidence concerns the gene LYZ and early-onset autosomal dominant Alzheimer disease.